The content of this presentation is provided to an audience of international healthcare professionals from around the world for scientific discussion and scientific exchange. Bayer does not recommend the use of any drug substance outside of its approved indications.

At the moment of publication, the compound presented has been only approved by Food and Drug Administration (FDA) and European Medicines Agency (EMA). For other approvals, follow your local regulations or health authorities legislation.

European Renal Association 59th Annual Meeting May 19–22, 2021

Presentations of the Bayer Industry Symposium at the European Renal Association 59th Annual Meeting Annual Meeting 2022

Thank you for your interest! See below to watch the session recording of the ERA symposium video chaired by Patrick Rossignol, with presentations from Jolanta Maylyszko, Roland Schmieder and George Bakris.

Finerenone
Nonsteroidal MRAs: A new hope for improved cardiorenal outcomes in patients with CKD and T2D


Saturday 21 May, 2022 | 13:30 - 14:30 CEST | On Demand
Nonsteroidal MRAs: A new hope for improved cardiorenal outcomes in patients with CKD and T2D
Despite current therapies, patients with CKD and T2D remain at risk of CKD progression and cardiovascular events. Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, is a new approved treatment to improve cardiorenal outcomes in patients with CKD and T2D. Clinical data from the phase III clinical trial programme will be used to highlight how to use finerenone in clinical practice and the importance of early diagnosis and personalised treatment regimens in patients with CKD and T2D.

Session type: Industry Symposium Faculty: George Bakris, Jolanta Malyszko, Patrick Rossignol, Roland Schmieder

Play Icon

View Video

More Information

For more information regarding Finerenone visit us by clicking the link below 
At the moment of publication, the compound presented has been only approved by Food and Drug Administration (FDA) and European Medicines Agency (EMA). For other approvals, follow your local regulations or health authorities legislation.

Date accessed: 14 April, 2022 

Doc Icon

Visit Link

The compendium provided by Bayer is a compilation of Bayer-sponsored presentations. Copies of presentations obtained from this compendium are for personal use only and may not be reproduced or distributed without permission from European Renal Association and from the authors.

Reused with permission. © 2022 European Renal Association (ERA 2022). All rights reserved.

For any questions, please contact Medical Information at 1-888-84-BAYER (1-888-842-2937), or visit go.bayer.com/vPIR.

MA-M_FIN-ALL-0850-1

© 2022 Bayer AG

The content of this presentation is provided to an audience of international healthcare professionals from around the world for scientific discussion and scientific exchange. Bayer does not recommend the use of any drug substance outside of its approved indications.

 

At the moment of publication, the compound presented has been only approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA). For other approvals, follow your local regulations or health authorities legislation.

 

Last updated on 01/06/2022